The U.S. National Institutes of Health is starting a pioneering, multi-pronged public-private partnership program to try to accelerate the development of Parkinson’s…
Articles by Patricia Inácio, PhD
Mutations in the LRRK2 gene, a major genetic factor contributing to Parkinson’s disease, may likely affect the risk for…
Deep brain stimulation (DBS) may help extend the survival of patients with Parkinson’s disease, according to a new…
Denali Therapeutics says its experimental therapy for Parkinson’s disease, DNL201 — a small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2)…
Mutations of genes responsible for breaking down and recycling cell waste products may promote Parkinson’s disease, a study shows. Scientists…
Weight loss in Parkinson’s disease patients increases the risks for dementia and dependency care, and reduces patients’ life expectancy, according…
Patients with moderate-to-severe Parkinson’s disease who received human neural stem cells in their brain as part of a Phase 1…
Acorda Therapeutics announced that it will now monitor blood cell counts on a weekly basis in Parkinson’s disease patients enrolled…
A new Phase 2a clinical trial, funded by The Michael J. Fox Foundation (MJFF), is now recruiting Parkinson’s disease…
Carbidopa, a medicine approved for the treatment of Parkinson’s disease, also has shown anti-cancer effects in lab-grown human cells and…